Table 3 Summary of hazard ratios for adverse events by three classes of anticancer drugs

From: Post-marketing surveillance of anticancer drugs using natural language processing of electronic medical records

 

Adjusted HR [95%CI] (p-value)

 

PN

OM

TA

AL

PLT

1.63 [1.53, 1.74] (<0.001) (Tx = 2505, NTx = 1654)

3.85 [3.47, 4.26] (<0.001) (Tx = 1878, NTx = 502)

4.71 [4.14, 5.35] (<0.001) (Tx = 1434, NTx = 300)

3.34 [3.11, 3.59] (<0.001) (Tx = 2688, NTx = 1198)

TAX

1.95 [1.80, 2.10] (<0.001) (Tx = 1848, NTx = 1127)

3.11 [2.75, 3.50] (<0.001) (Tx = 975, NTx = 377)

3.67 [3.18, 4.24] (<0.001) (Tx = 802, NTx = 248)

3.84 [3.50, 4.22] (<0.001) (Tx = 1417, NTx = 662)

PYA

1.15 [1.07, 1.24] (<0.001) (Tx = 2143, NTx = 1547)

3.70 [3.33, 4.11] (<0.001) (Tx = 2046, NTx = 491)

3.48 [3.05, 3.97] (<0.001) (Tx = 1333, NTx = 306)

1.98 [1.84, 2.13] (<0.001) (Tx = 2460, NTx = 1266)

  1. Hazard ratios with 95% confidence intervals and significance levels are shown. The number of cases with adverse events are also shown: Tx for the treatment group with adverse events and NTx for the non-treatment group with adverse events.
Back to article page